Positive response and disease control rates were observed in 2 separate studies when patients with head and neck squamous cell carcinoma (HNSCC) and melanoma received the combination of eganelisib (IPI-549), a selective PI3K-? inhibitor, and nivolumab (Opdivo).
Archive | Melanoma News
Eganelisib/Nivolumab Combo Shows Positive Responses in Head and Neck Carcinoma, Melanoma
Posted in Melanoma News, Health Professionals, Clinical Trials, Publications, Scientific Publications
Deciding Between Adjuvant Targeted Therapy and Immunotherapy in BRAF+ Melanoma
When selecting between an adjuvant targeted therapy or immunotherapy for a patient with melanoma, it’s important to consider several factors, including the biologic behavior of the tumor, any comorbidities, toxicities, and patient concerns, according to Reinhard Dummer, MD.
Posted in Melanoma News, Health Professionals, Of Interest, Publications, Scientific Publications
Improved dermoscopy training in residency should be prioritized
Dermoscopy training and education should be prioritized in resident education to increase melanoma detection, according to a study published in JAMA Dermatology.
Posted in Melanoma News, Health Professionals, Of Interest, Publications, Scientific Publications
Low-Dose IL-2 Shows Promise in Colitis
Low doses of the recombinant T-cell growth factor interleukin 2 (IL-2, aldesleukin, Proleukin) were well tolerated among patients with moderate-to-severe ulcerative colitis in a small 8-week study, with only one patient being withdrawn because of a dose-limiting toxicity, a researcher reported.
Posted in Melanoma News, Health Professionals, Of Interest, Publications, Scientific Publications
